334 completed, 49 unknown, 38 terminated, 15 recruiting. 453 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 453 | Completed 334, Unknown 49, Terminated 38, Recruiting 15, Withdrawn 9, Not yet recruiting 7, Active not recruiting 1 |
Follow Schizophrenia: new trials by email Literature Review of Schizophrenia trials Research Report on Schizophrenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of an IL-23 Inhibitor for Immune Activation in Clinical Trial of an IL-23 Inhibitor for Immune Activation in People With Schizophrenia Placebo, IL-23 - Schizophrenia, Schizo Affective Disorder | Phase 4 | Not yet recruiting | University of Maryland, Baltimore | 40 | 2026-09-01 | 2026-05-29 |
| A Study to Evaluate the Effect of KarXT on Urological Safety Xanomeline/trospium chloride - Schizophrenia | Phase 4 | Recruiting | Bristol-Myers Squibb | 60 | 2026-01-20 | 2026-10-19 |
| Bromocriptine for Patients With Schizophrenia and Prediabetes Bromocriptine - Schizophrenia, PreDiabetes | Phase 4 | Not yet recruiting | VA Pittsburgh Healthcare System | 15 | 2026-01-01 | 2025-09-22 |
| Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in Schizophrenia Paliperidone Palmitate Injection (PP1M) - Schizophrenia | Phase 4 | Not yet recruiting | Jiangsu Province Nanjing Brain Hospital | 120 | 2025-10-01 | 2025-09-29 |
| Efficacy and Safety of Paliperidone in Schizophrenia - Bangladesh Study Paliperidone extended-release (ER) - Schizophrenia | Phase 4 | Not yet recruiting | Sher-E-Bangla Medical College | 505 | 2025-09-01 | 2025-09-04 |
| A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Valbenazine - Schizophrenia, Schizoaffective Disorder | Phase 4 | Recruiting | Neurocrine Biosciences | 100 | 2025-08-29 | 2026-09-18 |
| Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR. Group A: (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol,anxiolytics: clonazepam, stedon, tavor antidepressants: seropram),, Group B (Pharmacotherapy and TAU) (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, antidepressants,, Group C (Pharmacotherapy and Psychotherapy) Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, lithium, depakine - Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder | Phase 4 | Active not recruiting | Dr. Stavroula Rakitzi | 84 | 2025-06-04 | 2026-05-01 |
| An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients Xanomeline/Trospium - Schizophrenia | Phase 4 | Not yet recruiting | Vanguard Research Group | 172 | 2025-04-16 | 2025-04-11 |
| An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in Participants With Schizophrenia Xanomeline and Trospium Chloride - Schizophrenia Disorders | Phase 4 | Not yet recruiting | Collaborative Neuroscience Research, LLC | 100 | 2025-04-01 | 2025-04-11 |
| Anticholinergic Deprescription in Schizophrenia Anticholinergic Deprescription, No Anticholinergic Deprescription - Schizophrenia, Schizoaffective Disorder | Phase 4 | Recruiting | Deepak K. Sarpal, M.D. | 105 | 2025-02-01 | 2026-07-10 |
| Biomarkers to Enhance Early Schizophrenia Treatment aripiprazole, risperidone, clozapine - Schizophenia Disorder | Phase 4 | Recruiting | Northwell Health | 180 | 2024-09-04 | 2026-07-31 |
| Maintenance Electroconvulsive Therapy (ECT) Versus Aripiprazole in Clozapine-resistant Schizophrenia maintenance ECT, Aripiprazole tablet - Clozapine Resistant Schizophrenia | Phase 4 | Unknown | All India Institute of Medical Sciences, Bhubaneswar | 40 | 2024-08-10 | 2024-07-16 |
| A Pilot Trial of Tapering Antipsychotics for Patients in Remitted Psychosis Co-administering With N-Acetylcysteine N-Acetylcysteine - Psychosis | Phase 4 | Not yet recruiting | National Taiwan University Hospital | 20 | 2024-08-01 | 2024-08-09 |
| The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. Clozapine, Second-line Antipsychotics (treatment as usual) - Schizophrenia and Related Disorders, Early Treatment-Resistance | Phase 4 | Recruiting | Dr. Inge Winter | 418 | 2024-08-01 | 2025-09-26 |
| Anti-Inflammatory Challenge in Schizophrenia Infliximab, Placebo - Schizophrenia | Phase 4 | Recruiting | Emory University | 60 | 2024-04-18 | 2026-06-03 |
| Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia Aripiprazole, Risperidone - Schizophrenia | Phase 4 | Completed | All India Institute of Medical Sciences, Bhubaneswar | 60 | 2024-04-05 | 2025-11-25 |
| Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia Lumateperone, Placebo - Schizophrenia, Schizo Affective Disorder | Phase 4 | Recruiting | University of Massachusetts, Worcester | 50 | 2024-04-02 | 2026-05-22 |
| C-Cog in Early Course Schizophrenia Study Aripiprazole Lauroxil, Computerized cognitive and functional skills training - Schizophrenia | Phase 4 | Terminated | University of Miami | 1 | 2024-01-23 | 2026-02-06 |
| Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis Aripiprazole, Paliperidone - Schizophrenia, Treatment-resistant Schizophrenia | Phase 4 | Unknown | Consorcio Centro de Investigación Biomédica en Red (CIBER) | 244 | 2023-11-01 | 2023-09-29 |
| Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder Sublingual film containing Igalmi - Bipolar Disorder, Schizophrenia | Phase 4 | Completed | BioXcel Therapeutics Inc | 29 | 2023-10-02 | 2026-08-11 |
Showing 20 of 453. Sign in to see all of them.
Psychotic Disorders (183) · Bipolar Disorder (27) · Metabolic Syndrome (16) · Diabetes Mellitus (12) · Mental Disorders (11) · Smoking Cessation (11) · Substance-Related Disorders (9) · Alcoholism (8) · Cognitive Dysfunction (8) · Insulin Resistance (8) · Obesity (8) · Tobacco Use Disorder (8) · Depression (7) · Depressive Disorder, Major (7)
Schizophrenia Spectrum and Other Psychotic Disorders (450) · Mental Disorders (442) · Behavior (41) · Nutritional and Metabolic Diseases (41) · Pathological Conditions, Signs and Symptoms (40) · Metabolic Diseases (37) · Glucose Metabolism Disorders (33) · Signs and Symptoms (30) · Bipolar and Related Disorders (27) · Mood Disorders (27) · Nervous System Diseases (23) · Hyperinsulinism (22) · Chemically-Induced Disorders (21) · Endocrine System Diseases (18) · Behavioral Symptoms (16)
Risperidone (100) · Aripiprazole (67) · Olanzapine (62) · Paliperidone Palmitate (43) · Quetiapine Fumarate (41) · ziprasidone (32) · Clozapine (29) · Amisulpride (17) · Haloperidol (15) · Metformin (14) · Varenicline (10) · Lurasidone Hydrochloride (9) · Antipsychotic Agents (7) · Sugars (7) · Therapeutics (7)
Eli Lilly and Company (16) · Massachusetts General Hospital (16) · AstraZeneca (10) · University of California, Los Angeles (10) · University of Maryland, Baltimore (10) · Janssen Korea, Ltd., Korea (9) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (9) · Shanghai Mental Health Center (8) · All India Institute of Medical Sciences, Bhubaneswar (7) · North Suffolk Mental Health Association (7) · Northwell Health (7) · Otsuka Pharmaceutical Development & Commercialization, Inc. (7) · University of Massachusetts, Worcester (7) · Central South University (6) · Duke University (6)
United States (193) · China (30) · Germany (30) · South Korea (27) · Taiwan (25) · Spain (20) · Canada (19) · United Kingdom (16) · Israel (15) · Brazil (12) · Denmark (12) · India (12) · Austria (10) · Australia (9) · Italy (9)
Alan I Green, MD (6) · Benedicto Crespo-Facorro, Professor (6) · Xiaoduo Fan, MD, MPH, MS (5) · A Eden Evins, MD, MPH (4) · Donald C Goff, M.D. (4) · Steven L Batki, MD (4) · T. Scott Stroup, MD, MPH (4)
PMID 38958149, PMID 37142273, PMID 20840778, PMID 21586165, PMID 21975110, PMID 26107752, PMID 29856773, PMID 30097769, PMID 31415936, PMID 40779812, PMID 10372604, PMID 10492856, PMID 11229973, PMID 11383973, PMID 11559786, PMID 11691689, PMID 12509667, PMID 12747876, PMID 12823080, PMID 14645311, PMID 14661862, PMID 14735295, PMID 15000267, PMID 15056517, PMID 15289699, PMID 15521794, PMID 15968344, PMID 16172203, PMID 16185814, PMID 16247923, PMID 16380684, PMID 16452559, PMID 16499883, PMID 16585434, PMID 16585435, PMID 16633199, PMID 16801664, PMID 16818861, PMID 16829550, PMID 16831113, PMID 16870959, PMID 17006758, PMID 17015817, PMID 17054789, PMID 17151158, PMID 17151159, PMID 17159456, PMID 17187911, PMID 17287825, PMID 17321111
2009 (5), N01MH090001 (4), N01MH90001 (3), P50MH060450 (2), P50MH066286 (2), R01MH037705 (2), R01MH049891 (2), R01MH060004 (2), 2008 (1), 2015 (1), 2023 (1), K23DA034034 (1), K23MH074540 (1), R01AA013655 (1), R01DA013196 (1)